{"id":"placebo-to-v920","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"V920 is an investigational HPV vaccine candidate in development by Merck Sharp & Dohme. As a therapeutic vaccine (rather than prophylactic), it is intended to generate cellular and humoral immune responses to target HPV-infected cells. The vaccine is being evaluated in Phase 3 trials for treatment of HPV-related diseases.","oneSentence":"V920 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:29:04.190Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HPV-related cervical intraepithelial neoplasia (CIN)"},{"name":"HPV-related oropharyngeal or anogenital lesions"}]},"trialDetails":[{"nctId":"NCT03031912","phase":"PHASE2","title":"African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-08-01","conditions":"Ebola","enrollment":251},{"nctId":"NCT05130398","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon","status":"COMPLETED","sponsor":"Centre de Recherche Médicale de Lambaréné","startDate":"2021-04-09","conditions":"Ebola Virus Disease","enrollment":120},{"nctId":"NCT02314923","phase":"PHASE1","title":"Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-12-05","conditions":"Ebola Virus","enrollment":513},{"nctId":"NCT02269423","phase":"PHASE1","title":"Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-10-13","conditions":"Ebola Virus","enrollment":39},{"nctId":"NCT02280408","phase":"PHASE1","title":"Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-10-07","conditions":"Ebola Viruses","enrollment":39},{"nctId":"NCT02503202","phase":"PHASE3","title":"Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-08-17","conditions":"Prevention of Ebola Infection","enrollment":1197}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo to V920","genericName":"Placebo to V920","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Biologic","firstApprovalDate":"","aiSummary":"V920 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) infection. Used for HPV-related cervical intraepithelial neoplasia (CIN), HPV-related oropharyngeal or anogenital lesions.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}